Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy

Journal of Surgical Oncology

Volumn 102, Issue 8, 2010, Pages 1002-1008

  Thomay, Alan A ^a   Charpentier, Kevin P ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

cancer; colorectal; liver; metastases; surgery

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

BLEEDING; CANCER CHEMOTHERAPY; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FATTY LIVER; HUMAN; LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; WOUND HEALING;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING;

EID: 78650667210     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21694     Document Type: Review

References (69)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Wingo PA, Tong T, Bolden S,: Cancer statistics, 1995. Ca Cancer J Clin 1995; 45: 8-30.
3. American Cancer Society. Detailed Guide: Colon and Rectum Cancer page. Available at: http://www.cancer.org. Accessed 4/15/2010.
4. Van Cutsem E, Nordlinger B, Adam R, et al.: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221.
5. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
6. Kemeny N,: Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006; 20: 1161-1176.
7. Bengmark S, Hafström L,: The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969; 23: 198-202.
8. Bengtsson G, Carlsson G, Hafström L, et al.: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-589.
9. Hughes KS, Simon R, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence. Surgery 1986; 100: 278-284.
10. Scheele J, Stang R, Altendorf-Hofmann A, et al.: Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
11. Nordlinger B, Guiguet M, Vaillant JC, et al.: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262.
12. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
13. Figueras J, Valls C, Rafecas A, et al.: Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88: 980-985.
14. Adam R,: Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14: ii13-ii16. (Pubitemid 36874133)
15. Fong Y,: Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49: 231-255. (Pubitemid 29525144)
16. Charnsangavej C, Clary B, Fong Y, et al.: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1261-1268.
17. Elias D, Ouellet JF, Bellon N, et al.: Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003; 90: 567-574.
18. Kamel IR, Choti MA, Horton KM, et al.: Surgically staged focal liver lesions: Accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003; 227: 752-757.
19. Bipat S, van Leeuwen MS, Comans EF, et al.: Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-Meta-analysis. Radiology 2005; 237: 123-131.
20. Kinkel K, Lu Y, Both M, et al.: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002; 224: 748-756.
21. Jarnigan WR, Fong Y, Ky A, et al.: Liver resection for metastatic colorectal cancer: Assessing the risk of occult irresectable disease. J Am Coll Surg 1999; 188: 33-42.
22. Kim MJ, Kim JH, Chung JJ, et al.: Focal hepatic lesions: Detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003; 228: 719-726.
23. Ward J, Guthrie JA, Wilson D, et al.: Colorectal hepatic metastases: Detection with SPIO-enhanced breath-hold MR imaging-Comparison of optimized sequences. Radiology 2003; 228: 709-718.
24. del Frate C, Bazzocchi M, Mortele KJ, et al.: Detection of liver metastases: Comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 2002; 225: 766-772.
25. Auer RC, White RR, Kemeny NE, et al.: Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509.
26. Huebner RH, Park KC, Shepherd JE, et al.: A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189.
27. Ruers TJ, Wiering B, van der Sijp JR, et al.: Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: A randomized study. J Nucl Med 2009; 50: 1036-1041.
28. Selzner M, Hany TF, Wildbrett P, et al.: Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 1027-1034.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
30. Trillet-Lenoir V, Freyer G, Kaemmerlen P, et al.: Assessment of tumour response to chemotherapy for metastatic colorectal cancer: Accuracy of the RECIST criteria. Br J Radiol 2002; 75: 903-908.
31. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
32. Chapman WC, Hoff PM, Strasberg SM,: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement by Charnsangavej et al. Ann Surg Oncol 2006; 13: 1269-1270.
33. Pozzo C, Basso M, Cassano A, et al.: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939.
34. André T, Boni C, Mounedji-Boudiaf L, et al.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
35. André T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
36. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
37. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
38. Tournigand C, André T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
39. Colucci G, Gebbia V, Paoletti G, et al.: Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
40. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
41. Bartlett DL, Berlin J, Lauwers GY, et al.: Chemotherapy and regional therapy of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1284-1292.
42. Rougier P, Van Cutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
43. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
44. Saltz LB, Clarke S, Díaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
45. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
46. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
47. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
48. Dempke WC, Heinemann V,: Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009; 45: 1117-1128.
49. Heinemann V, Stintzing S, Kirchner T, et al.: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 262-271.
50. Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
51. Van Cutsem E, Köhne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
52. Bouché O, Beretta GD, Alfonso PG, et al.: The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treat Rev 2010; 36: S1-S10.
53. Portier G, Elias D, Bouche O, et al.: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982.
54. Nordlinger B, Sorbye H, Glimelius B, et al.: EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016.
55. Parks R, Gonen M, Kemeny N, et al.: Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents. J Am Coll Surg 2007; 204: 753-761.
56. Washington K, Lane KL, Meyers WC,: Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol 1993; 17: 1151-1158.
57. Fernandez FG, Ritter J, Goodwin JW, et al.: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853.
58. D'Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 2007; 14: 759-765.
59. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
60. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657.
61. Rivoire M, De Cian F, Meeus P, et al.: Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002; 95: 2283-2292.
62. Abdalla EK, Adam R, Bilchik AJ, et al.: Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280.
63. Adams RB, Haller DG, Roh MS,: Improving resectability of hepatic colorectal metastases: Expert consensus statement by Abdalla et al. Ann Surg Oncol 2006; 13: 1281-1283.
64. Rubbia-Brandt L, Giostra E, Brezault C, et al.: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
65. Benoist S, Brouquet A, Penna C, et al.: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006; 24: 3939-3945.
66. Adam R, Wicherts DA, de Haas RJ, et al.: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 2008; 26: 1635-1641.
67. Blazer DG III, Kishi Y, Maru DM, et al.: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
68. Elias D, Goere D, Boige V, et al.: Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: Impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194.
69. Chun YS, Vauthey JN, Boonsirikamchai P, et al.: Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302: 2338-2344.